Tempus AI Is Ripping 30% Higher This Week After Morgan Stanley Boosts Revenue Outlook

Tempus AI Is Ripping 30% Higher This Week After Morgan Stanley Boosts Revenue Outlook Rich Duprey Fri, September 18, 2026 at 12:47 AM GMT+9 4 min read TEM +14.41% Quick Read TEM surged 30% this week after Morgan Stanley spotlighted reimbursement pricing that could add between $330M and $400M in combined annual revenue across xT and xF diagnostics.

Lefkofsky says Tempus will exceed its 25% multiyear growth target, with $200M in Q2 data licensing bookings from AstraZeneca, GSK, and Merck fueling confidence.

Despite a 54% one-month gain, TEM still trades below its $104 52-week high as the $68 analyst consensus target now lags the market price.

Tempus AI (NASDAQ:TEM) is having a breakout week after Morgan Stanley remarks on September 15 spotlighted fresh reimbursement-driven revenue lifts for the AI-powered diagnostics company. Shares have rallied 29.98% over the past week, extending into a 13.83% surge in Thursday's session to $79.65. For long-term investors, the commentary reframes the near-term revenue trajectory well beyond management's prior guidance.

The Morgan Stanley discussion centered on how newly clarified reimbursement pricing translates directly into incremental revenue. CEO Eric Lefkofsky estimated that xT pricing adds $80 million to $100 million next year, while xF approval and pricing could add $250 million to $300 million annually. Lefkofsky also signaled that Tempus should over-deliver on its stated 25% multiyear growth target.

Those figures line up with prepared remarks from the Q2 call, where management guided to approximately $400 million of revenue uplift in 2028 across the XT CDx and XF approvals, and pegged the minimal residual disease opportunity from the pending Personalis deal at a $20 billion plus market.

One investment mistake could create big risks for your retirement. Many investors make the same critical errors: being too conservative, making big bets on "sure things," or paying excessive fees. Any of those blunders can endanger your hard-earned savings.

Now you can learn the mistakes even experienced investors make (and ways you can sidestep them before it's too late) with this new guide: 13 Retirement Mistakes and How to Avoid Them from Fisher Investments. Access your complimentary copy here (sponsor)

Tempus is a Chicago-based precision medicine platform with two segments: Diagnostics and Data and Applications. Q2 FY2026 revenue reached $382.49 million, up 21.6% year over year, with oncology testing volumes accelerating 31%. The company raised full-year guidance to $1.595 to $1.605 billion, or roughly 25% annual growth, and reaffirmed adjusted EBITDA of about $65 million. Market capitalization sits near $14.0 billion.

Data licensing bookings totaled approximately $200 million in the quarter, with named customers including AstraZeneca, GlaxoSmithKline, Bristol-Myers Squibb, Merck, Daiichi Sankyo, Levelset Bio, and Insight Pharmaceuticals. Lefkofsky said "The data business is just on fire."

The setup matters because analyst sentiment was already turning. Forward EPS estimates for fiscal 2027 have swung from -$0.1067 ninety days ago to $0.0040 today, with eight upward revisions in the past 30 days. Wall Street's consensus revenue estimate for FY2027 sits at $1.97 billion. Shares trade at roughly 9x sales, and the stock remains below its 52-week high of $104.32 despite a 54.24% one-month gain. The consensus analyst target price of $68.18 now trails the market price, suggesting further target revisions may follow.

Retirement-focused readers should weigh Tempus AI stock as a high-beta growth story: beta of 3.7, ongoing GAAP losses, and heavy stock-based compensation of $54.1 million in Q2. Yet the reimbursement clarity, accelerating data licensing, and pending Personalis MRD platform sharpen a credible path to positive free cash flow by year end. The price target raised commentary from Morgan Stanley reframes the setup, though position sizing should reflect the volatility that comes with it (we studied what the early traits of the biggest tech winners looked like and put them in a free playbook here).

Now you can learn the mistakes even experienced investors make (and ways you can sidestep them before it's too late) with this new guide: 13 Retirement Mistakes and How to Avoid Them from Fisher Investments. (sponsor)

Contact editorial@247wallst.com for any questions or corrections.